Henninger S, Schatz H, Stracke H, Wagner U, Kracht J
3rd Medical Department, University of Giessen, FRG.
Acta Histochem. 1988;83(1):51-6. doi: 10.1016/S0065-1281(88)80071-0.
Immunohistochemical determinations in tissue specimens of medullary and "undifferentiated" thyroid carcinomas were carried out with antisera against calcitonin, calcitonin-gene related peptide (CGRP), somatostatin, and also thyroglobulin, using the PAP method. All 8 samples of medullary carcinoma stained positive with antisera against calcitonin and CGRP, 7 samples were also positive for somatostatin. Out of 22 cases initially diagnosed as "undifferentiated thyroid carcinoma" 3 revealed positivity for calcitonin, 2 for CGRP, and 1 for somatostatin. Congo red stain for amyloid, performed several years ago in 2 of these 3 cases, had been negative. The patients with medullary carcinoma survived longer than those with "undifferentiated" carcinoma. One patient of the latter group, but with calcitonin, CGRP, and somatostatin immunoreactivity in the tumour tissue, is now alive and well, more than 4 a after initial treatment.
采用PAP法，使用抗降钙素、降钙素基因相关肽（CGRP）、生长抑素以及甲状腺球蛋白的抗血清，对髓样甲状腺癌和“未分化”甲状腺癌的组织标本进行免疫组织化学测定。所有8例髓样癌样本对抗降钙素和CGRP的抗血清染色呈阳性，7例样本对生长抑素也呈阳性。在最初诊断为“未分化甲状腺癌”的22例病例中，3例降钙素呈阳性，2例CGRP呈阳性，1例生长抑素呈阳性。几年前对这3例中的2例进行的淀粉样蛋白刚果红染色为阴性。髓样癌患者的存活时间比“未分化”癌患者长。后一组中有1例患者，其肿瘤组织中有降钙素、CGRP和生长抑素免疫反应性，在初始治疗后4年多现在仍然健在且状况良好。
